🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to present a poster at #SITC24 Society for Immunotherapy of Cancer on work led by Mireiaa. We will share data on miniprotein based immunotherapeutics that are functional in an animal model for acute myeloid leukemia. Check out the abstract here: jitc.bmj.com/content/12/Sup…

FT825/ONO-8250, a HER2 CAR-T cell therapy co-developed by Fate Therapeutics and ONO PHARMACEUTICAL and now in Phase 1 trials, incorporates advanced engineering techniques. The challenge in HER2 CAR-T development extends beyond merely applying CAR-T cell therapy to solid tumors;

We've got some very exciting news to share! businesswire.com/news/home/2024… and here's a 🧵 about the journey from academia to AI Proteins

AI Proteins is excited to partner with Bristol Myers Squibb to develop novel miniprotein-based therapeutics. This collaboration will leverage our cutting-edge AI-driven platform to design and optimize miniproteins with the potential to transform patient outcomes. businesswire.com/news/home/2024…

You can read more about our exciting new collaboration with Bristol Myers Squibb in this coverage from Fierce Biotech fiercebiotech.com/biotech/bristo…

💫🌟🎯 NECTIN4 Amplification Predicts Enfortumab Vedotin Response in mUC🌟💫 OncoAlert 🔬 Key finding: NECTIN4 amplification predicts a 96% objective response to Enfortumab Vedotin (EV) in metastatic urothelial cancer (mUC). 📈 Survival: NECTIN4 amplification reduces the risk

See Mireia Solà Colom Mireiaa, Head of Immunotherapeutics at AI Proteins, as she presents our latest progress on the design and optimization of immune cell engagers built from our de novo #miniproteins

Site-saturation mutagenesis of 500 human protein domains | Nature nature.com/articles/s4158…

A socratic dialogue over the utility of DNA language models (Part 1 of 2) here's the link: owlposting.com/p/a-socratic-d… and here's a longpost of why i wrote this: i think the effort that went into Evo 2 is very cool and its clearly a very comprehensive paper but the excitement

CONFERENCES | On Feb 2025, IIBM UC PhD student Aransa Griñen gave a fantastic talk on the design of novel PET-degrading enzymes using deep learning, in collaboration with AI Proteins, during the 2025 edition of Winter RosettaCon from Rosetta Commons in Boston

Extremely clever new NGS tech from Roche 🧬 If it's hard to discriminate between nucleic acids accurately with a nanopore, why not synthesize a new polymer off a DNA template that is easier to sequence? It's an intuitively simple idea, but took *a ton* of creative nucleic acid

Preprint from Roche: doi.org/10.1101/2025.0…

Excited to share this work from the Garcia Lab out today in Nature Communications! We engineer "cytokine adaptors", molecular switches that simultaneously block a target cytokine while inducing local activation of alternative cytokine receptors. rdcu.be/ec7GS

Dear Biotech Investment Community🙇 I just posted a deep-dive thread on $VKTX — analyzing their impressive PK profile and the science behind it. If you find it helpful, I’d be truly grateful for a RT or follow. Your support keeps me going, and I’ll keep sharing data-driven

Scalable and cost-efficient custom gene library assembly from oligopools biorxiv.org/content/10.110… #biorxiv_synbio

De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors 🚀 New preprint from David Baker!🚀 1. This paper introduces a computational and experimental approach for designing miniproteins targeting G protein-coupled receptors (GPCRs) with

Small proteins can be more complex than they look! We know proteins fluctuate between different conformations- but how much? How does it vary protein to protein? Can highly stable domains have low stability segments? Állan Ferrari experimentally tested >5,000 domains to find out!

I am so grateful to be back on the TED stage this week in Vancouver to share an update on our story. In the 6 years since my last TED talk, I left academia and founded AI Proteins. I can't wait to tell you about what we've been building. businesswire.com/news/home/2025…

Wow, wow, wow!!! The structure of human sweetness cell.com/cell/fulltext/…

Excited to share our new Science Magazine paper! Led by postdocs Ruchao Peng and Xin Xu, we used cryo-EM/ET to reveal the influenza ribonucleoprotein complex structure and its strand-sliding mechanism for RNA synthesis, paving the way for new antivirals. science.org/doi/10.1126/sc…